Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Batroxobin Injection Post-Marketing Safety Study in Acute Ischemic Stroke
CTR20260113Phase 4Active
- Sponsor
- Beijing Tobishi Pharmaceutical Co., Ltd.
- Start
- Feb 2026
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of recombinant batroxobin in ischemic stroke and brain infarction, sponsored by Beijing Tobishi Pharmaceutical Co., Ltd. Started Feb 2026; status: active.
02
Drugs
recombinant batroxobin
03
Conditions
ischemic strokebrain infarction
Beyond the preview
Go deeper on CTR20260113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260113.